Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with ...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...